Targeting Apoptosis as a Strategy for Developing New Drugs
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 2036
Special Issue Editors
Interests: cell biology; cancer cells; cell signaling; oxidative stress; cytotoxicity
Special Issues, Collections and Topics in MDPI journals
2. Biotechnology Centre, Silesian University of Technology, 44-100 Gliwice, Poland
Interests: medicinal chemistry; carbohydrate chemistry; glycoconjugates; organosulfur compounds; anticancer compounds; enzyme inhibitors
Special Issue Information
Dear Colleagues,
Regulated cell death (RCD) plays a significant role in the homeostasis of the body, both in physiological and pathological conditions. Excessive or insufficient RCD can cause diseases. RCD can take many forms, including apoptosis, necroptosis, or ferroptosis. Cells may be sensitive or resistant to different death types, which depends on the cell’s origin and treatment. For a long time, a considerable amount of interest has been paid towards searching for less well-known anticancer agents, especially with proapoptotic activities. They were found to be good targets for drug repurposing because of their proven safety, inexpensiveness, quality, and well-known ways of synthesis. Some of them exhibit a wide range of biological activities, such as anticancer, antiviral, anti-inflammatory, immunosupressive, antibacterial, and reversal of multidrug resistance. A variable type of biologically active molecules, natural or artificially synthesized, were used during the 19th–20th centuries due to their health benefits. However, validated studies of their derivatives, based on different nanoparticles, composed drug delivery systems, encapsulates, etc., with an effect on malignant tumor cells, have only begun within the last few decades. Proapoptotic agents and inducers of cellular death pathways are still the best players in anticancer strategies.
Dr. Magdalena Skonieczna
Dr. Anna Kasprzycka
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- proapoptotic drugs
- cellular death
- death pathways
- cell signaling
- apoptosis inductors
- intracellular death executors
- crosstalk of signaling pathways
- regulatory cell death (RCD)
- regulation of cell death
